Virus News and Research

Latest Virus News and Research

New research report outlines growth prospects of Biomagnetics Diagnostics

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced the Company is the subject of a new research report issued by Emerging Growth Research, LLP.

8 Oct 2009

LeVOCC air purification system destroys H1N1 virus

LeVOCC, Inc. today announced that independent laboratory testing has conclusively demonstrated that the LeVOCC(TM) air purification system successfully destroys a strain of the H1N1 virus.

8 Oct 2009

HHS unveils several new resources on federal government’s website for flu information

HHS Secretary Kathleen Sebelius today unveiled several new resources on the federal government’s one-stop resource for flu information -- www.flu.gov. The Web site now features a new H1N1 Flu Self-Evaluation guide for adults 18 and older along with a new Flu Myths and Facts section, which provides the public with the latest and most accurate information about the flu.

8 Oct 2009

Rite Aid pharmacists provide regular seasonal flu shots to help prevent flu

Patients have more options than ever this year at their local Rite Aid pharmacy to help prevent the flu. More than 2,000 Rite Aid certified immunizing pharmacists in more than 1,500 Rite Aid stores have been giving regular seasonal flu shots and will continue to do so throughout the flu season.

8 Oct 2009

New study finds rare type of head and neck cancer caused by HPV

An increase in cases of a rare type of head and neck cancer appears to be linked to HPV, or human papillomavirus, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

8 Oct 2009

Experts to develop effective surveillance system to monitor emerging infections at global level

Avian influenza (H5N1), rabies, plague, Bovine Spongiform Encephalopathy (BSE), and more recently swine flu (H1N1) are all examples of diseases that have made the leap from animals to humans.

8 Oct 2009

Researchers identify tumor-suppressing genes to diagnose the phase of laryngeal cancer

Researchers at Henry Ford Hospital have identified tumor-suppressing genes that may provide a more accurate diagnosis of disease stage and survival for laryngeal cancer patients than current standards.

8 Oct 2009

The Prescription Center Pharmacy launches 'Be Prepared, Not Scared' campaign

The Prescription Center Pharmacy, headquartered in Beverly Hills, California announced its “Be Prepared, Not Scared” campaign today. The purpose of the campaign is to help both businesses and consumers stay healthy, without dramatically changing their daily routines. Dr. Afshin Nassir, the pharmacy’s Founder and CEO, states that “We want to help businesses and consumers create a realistic plan to deal with the H1N1 (Swine Flu) Virus, which is now, according to the Center for Disease Control (CDC), at a Pandemic stage.”

8 Oct 2009

WHO emphasizes H1N1 vaccine safety

The WHO on Tuesday continued to express confidence in the H1N1 (swine flu) vaccine as few mild adverse effects have been reported by patients participating in China's vaccine campaign, the Associated Press reports. Out of the 39,000 people in China who received the H1N1 vaccine, four reported experiencing side effects such as muscle cramps and headache, according to WHO spokesman Gregory Hartl (Higgins, 10/6).

8 Oct 2009

Swine Flu prevention tips from California dentists

In keeping with the global effort to limit the spread of the Swine Flu, the California Dental Hygienists’ Association (CDHA) issued a list today of simple ways patients and oral health professionals can prevent catching and spreading the disease.

8 Oct 2009

Amarillo Biosciences, Intas Pharmaceuticals enter strategic partnership to combat influenza in India

Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.

8 Oct 2009

NCI awards $11.5 million grant to UAB for cervical cancer research

The University of Alabama at Birmingham (UAB) Comprehensive Cancer Center has won an $11.5 million grant from the National Cancer Institute (NCI) to explore groundbreaking cervical cancer research, prevention and treatment.

8 Oct 2009

Peregrine Pharmaceuticals establishes a new Anti-Viral Research Group

Peregrine Pharmaceuticals, Inc. today announced that it has established a new Anti-Viral Research Group in its R&D organization.

7 Oct 2009

Microsoft launches a new online H1N1 Flu Response Center

With the current H1N1 flu (swine flu) pandemic under way, many public health officials are concerned that critical healthcare resources could be stretched thin as people flood hospital emergency departments and physicians' offices to determine whether they have the illness.

7 Oct 2009

Idera Pharmaceuticals commences phase 1 IMO-2125 clinical trial for chronic HCV infection

Idera Pharmaceuticals, Inc. today announced that patient treatment has been initiated in a phase 1 clinical trial evaluating IMO-2125 in combination with ribavirin in treatment-naive patients with chronic hepatitis C virus (HCV) infection. IMO-2125 is a novel agonist of Toll-like Receptor (TLR) 9.

7 Oct 2009

Baxter receives marketing authorization for CELVAPAN H1N1 pandemic influenza vaccine

Baxter International Inc. today confirmed that the European Commission (EC) has granted marketing authorization for CELVAPAN H1N1 pandemic vaccine using Baxter’s Vero cell technology. CELVAPAN H1N1 is the first cell culture-based and non-adjuvanted pandemic influenza vaccine to receive marketing authorization in the European Union.

From Baxter International Inc. 7 Oct 2009

GlobeImmune to present an abstract of GI-5005 drug at AASLD's annual meeting

GlobeImmune Inc. today announced that a late breaking abstract related to GI-5005, its investigational hepatitis C virus (HCV) product candidate, has been accepted for presentation at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place Oct. 31 through Nov. 4, 2009, in Boston, Mass.

7 Oct 2009